Holen Sie sich die Stockscreener-App
0.668
0.83%
-0.0056
Schlusskurs vom Vortag:
$0.6736
Offen:
$0.66
24-Stunden-Volumen:
60,330
Relative Volume:
0.71
Marktkapitalisierung:
$17.57M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-60.11M
KGV:
-0.1537
EPS:
-4.347
Netto-Cashflow:
$-12.04M
1W Leistung:
-3.88%
1M Leistung:
-21.87%
6M Leistung:
-33.86%
1J Leistung:
-13.25%
1-Tages-Spanne:
$0.51
$0.6819
1-Wochen-Bereich:
$0.51
$0.7476
52-Wochen-Spanne:
$0.51
$1.45
AEON Biopharma Inc. Stock (AEON) Company Profile
Firmenname
AEON Biopharma Inc.
Sektor
Branche
Telefon
(949) 354-6499
Adresse
5 Park Plaza, Suite 1750, Irvine
Compare AEON vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AEON
AEON Biopharma Inc.
|
0.668 | 17.57M | 0 | -60.11M | -12.04M | -4.347 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 114.63B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.13B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 34.65B | 742.00K | -1.37B | -1.07B | -7.0731 |
AEON Biopharma Inc. Stock (AEON) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-08-18 | Eingeleitet | H.C. Wainwright | Buy |
AEON Biopharma Inc. Aktie (AEON) Neueste Nachrichten
AEON Biopharma shareholders approve directors and auditor slate - TipRanks
Aeon Biopharma Inc (AEON) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Aeon Biopharma Inc (AEON) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
AEON Biopharma, Inc. Elects Each of Marc Forth and Seongsoo Park as Class III Directors of the Company's Board of Directors - marketscreener.com
AEON Biopharma (NYSE: AEON) investors back Class III board slate and KPMG - Stock Titan
Aeon Biopharma Inc (AEON) Institutional Confidence - TradingKey
Aeon Biopharma Inc (AEON) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Aeon Biopharma Inc (AEON) Valuation: PE, PB & Fair Value Analysis - TradingKey
Aeon Biopharma Inc (AEON) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Aeon Biopharma Inc (AEON) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aeon Biopharma Inc (AEON) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
AEON Biopharma (AEON) Slides 7% as Selling Pressure Intensifies Near $0.67Wave Extension - newsline.com
AEON Biopharma (AEON) Holds Steady at $0.71 as Stock Consolidates Between Key Support and ResistanceSeasonality Effect - newsline.com
AEON Q4 2025 Earnings: Significant EPS Miss as Pre-Revenue Biotech Faces ChallengesRetail Earnings Report - newsline.com
Number of shareholders of AEON Biopharma, Inc. – AMEX:AEON - TradingView
AEON BIOPHARMA INC (AEON) Stock Chart - ChartMill
AEON Biopharma Presents New Data Supporting Biosimilarity of ABP-450 to BOTOX at AHS 2026 Annual Meeting - Moomoo
AEON Biopharma to Present Data Demonstrating Structural and Functional Comparability of ABP-450 to BOTOX® at the 68th Annual Scientific Meeting of the American Headache Society - The Manila Times
Botox biosimilar ABP-450 shows similar structure and activity - Stock Titan
AEON Technical Analysis | Trend, Signals & Chart Patterns | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON Biopharma (AEON) Surges 5.6% as Bulls Test Key Resistance at $0.80Factor ETF Flow - newsline.com
AEON Biopharma Edges Higher: Stock Rises 2.75% as it Tests Key ResistanceHigh Conviction Picks - The Legal Advocate
AEON Q4 2025 Earnings: Deep EPS Miss Amid Pre-Revenue StageEPS Miss Report - The Legal Advocate
AEON Biopharma Q4 2025 Earnings: Major EPS Miss and No Revenue Weigh on Investor SentimentEarnings Expansion Phase - Newser
AEON Biopharma Inc. (AEON) Q4 2025 Earnings: Significant EPS Miss and Stock Decline Amid Development ChallengesHigh Growth Earnings - Newser
AEON Biopharma Dips 2.74% as Stock Nears Critical Support at $0.76Watchlist Stock Ideas - Newser
AEON Q4 2025 Earnings: Wider-Than-Expected Loss as Biotech Continues Pre-Revenue PhaseAnalyst Earnings Estimate - newsline.com
12 Health Care Stocks Moving In Monday's Intraday Session - Sahm
AEON Stock Price, Quote & Chart | AEON BIOPHARMA INC (NYSEARCA:AEON) - ChartMill
AEON SEC FilingsAeon Biopharma 10-K, 10-Q, 8-K Forms - Stock Titan
AEON Biopharma shares fall over 2% on quarterly loss - Investing.com
AEON Biopharma shares fall over 2% on quarterly loss By Investing.com - Investing.com South Africa
AEON Biopharma Reports Q1 Financial Results - Intellectia AI
AEON Biopharma Releases Updated Investor Relations Presentation - TipRanks
AEON Biopharma Reports First Quarter 2026 Financial Results and Provides Corporate Update - The Manila Times
AEON Biopharma (AEON) releases May 2026 corporate investor presentation via Form 8-K - Stock Titan
AEON Biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
AEON Biopharma (NYSE: AEON) Q1 2026 loss, financing deals and going concern risk - Stock Titan
AEON Biopharma (NYSE: AEON) Q1 2026 loss, FDA boosts ABP-450 plan and debt cut - Stock Titan
AEON’s Botox biosimilar plan gets FDA feedback as debt falls 90% - Stock Titan
TradingKey - TradingKey
AEON Biopharma (AEON) details 2026 meeting, director elections and KPMG ratification - Stock Titan
AEON Biopharma Sets Annual Shareholder Meeting - The Manila Times
AEON cites going concern audit note, cash into Q3 2026 - Stock Titan
AEON Biopharma receives additional NYSE American non-compliance notice - MSN
AEON Bio (AEON) Stock: Why Brand Strength (Eye on Rally) 2026-04-20Market Movers - Cổng thông tin điện tử tỉnh Tây Ninh
Migraine Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | Eli Lilly and Company, Axsome Therapeutics, AEON Biopharma, Charleston Laboratories, Amgen, Teva Pharma, Anne Lindblad - Barchart.com
AEON (AEON Biopharma) PB Ratio : (As of Apr. 10, 2026) - GuruFocus
Form 10-QQuarterly report [Sections 13 or 15(d)] - ADVFN
Weekly Earnings: Will AEON Biopharma Inc be affected by tariffs2026 Big Picture & High Conviction Investment Ideas - baoquankhu1.vn
What is the bull case for AEON Bio (AEON) Stock | AEON Q4 2025 Earnings: AEON Biopharma Inc. misses EPS, no revenue postedAnnual Earnings Summary - newsline.com
Finanzdaten der AEON Biopharma Inc.-Aktie (AEON)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.74%
1.44%
Kapitalisierung:
|
Volumen (24h):